News & Updates

New drug applications approved by US FDA as of 16-31 January 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with aspirin, warfarin, and nonvitamin K oral anticoagulant (NOAC) results in a reduced risk of thromboembolic events, suggests a recent study.

Treatment with torsemide in survivors of heart failure hospitalization appears to have a similar effect on all-cause mortality over 12 months as furosemide, according to data from the open-label TRANSFORM-HF study.

New users of sacubitril-valsartan (SV) show no increased risk of angioedema when compared to users of angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB), reports a study.

Treatment with finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist with a short half-life, results in decreased 24-h, daytime, and night-time systolic blood pressure (SBP), results of a study have shown.

Supplementation with omega-3 fatty acids helps reduce triglyceride levels in postmenopausal women, according to a study. This supplement also leads to a modest increase in high- (HDL-C) and low-density lipoprotein cholesterol (LDL-C).